Previous close | 0.6600 |
Open | 0.2500 |
Bid | 0.0000 |
Ask | 0.6000 |
Strike | 165.00 |
Expiry date | 2024-06-21 |
Day's range | 0.2500 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 64 |
It's been a good week for Biogen Inc. ( NASDAQ:BIIB ) shareholders, because the company has just released its latest...
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.